Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM).

Neuro-oncology: a selected review of ASCO 2016 abstracts

“…Multiple Phase I trials were presented including the use of a brain penetrating pan-proteasome inhibitor, marizomib in conjunction with bevacizumab; a brain-penetrant PI3K/mTOR inhibitor, GDC-0084; T cells redirected to EGFRvIII with a chimeric antigen receptor; dianhydrogalactitol (VAL-083), a bi-functional alkylating agent that readily crosses the bloodbrain barrier; intratumoral viral delivery of the adenovirus vector, Ad-RTS-IL-12 and the activator ligand veledimex; TPI287, a brain penetrable third-generation taxane used in combination with bevacizumab; MLN0128 an oral TORC1/2 inhibitor in combination with bevacizumab; plerixafor, a CXCR4 antagonist (the CXCL12/CXCR4 axis is instrumental in radiation induced tumor vasculature recovery), given in combination with RT + TMZ; AZD 1775, a first in class Wee1 inhibitor; carboxyamidotriazole orotate (an oral inhibitor of nonvoltage dependent calcium signaling) and RT with concurrent and adjuvant TMZ; pembrolizumab in combination with bevacizumab; nivolumab with or without bevacizumab; and S49076, an oral multitarget inhibitor of c-MET, AXL, FGFR in combination with bevacizumab [22][23][24][25][26][27][28][29][30][31][32][33][34][35].…”